Lixte Biotechnology Holdings, Inc. (LIXT)
Automate Your Wheel Strategy on LIXT
With Tiblio's Option Bot, you can configure your own wheel strategy including LIXT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LIXT
- Rev/Share 0.0
- Book/Share 0.2395
- PB 17.8736
- Debt/Equity 0.0
- CurrentRatio 1.8427
- ROIC -4.7248
- MktCap 19522634.0
- FreeCF/Share -0.9602
- PFCF -7.4735
- PE -3.7692
- Debt/Assets 0.0
- DivYield 0
- ROE -3.0856
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced that Geordan Pursglove, its chief executive officer, will present at the Spartan Capital Investor Conference 2025 in New York, on November 3, 2025, at 4 p.m.
Read More
24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
LIXTE (NASDAQ: LIXT) publishes new data showing that its lead compound LB-100 can mediate activation of oncogenic signaling, which is toxic to cancer cells
Read More
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
Published: August 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways, Nature Reviews Cancer editorial titled “Too Much of a Good Thing”, which explores a counterintuitive cancer therapy approach that underscores the growing promise of its lead compound, LB-100 Nature . The editorial underscores LIXTE's first-in-class PP2A inhibitor, LB-100, and its revolutionary potential to exploit oncogenic signaling for cancer …
Read More
LIXTE Biotechnology Holdings Provides Corporate Update
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- - Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE's Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- PASADENA, Calif, Aug. 18, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities. “This has been a transformative period for our company,” …
Read More
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement
Published: July 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
New York, NY, July 08, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $5.0 million private placement for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.
Read More
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common stock at a purchase price of $2.415 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants will have an exercise price of …
Read More
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the “SEC”) of the Company's Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been …
Read More
About Lixte Biotechnology Holdings, Inc. (LIXT)
- IPO Date 2007-10-25
- Website https://lixte.com
- Industry Biotechnology
- CEO Bastiaan van der Baan
- Employees 2